60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Saturday morning,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $0.62 on Friday. The firm has a market capitalization of $1.43 million, a PE ratio of -0.06 and a beta of 4.24. The stock’s fifty day moving average is $1.16 and its 200 day moving average is $1.07. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $7.20.

Insider Activity

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow acquired 35,823 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the acquisition, the chief executive officer now directly owns 94,580 shares in the company, valued at $120,116.60. The trade was a 60.97 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have acquired 66,372 shares of company stock valued at $82,410. 10.27% of the stock is currently owned by insiders.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.